Loading
companiesCompany
Onc.AI
Onc.AI trains artificial intelligence on routine CT scans to predict early whether a lung cancer patient's immunotherapy is working, so doctors and drug developers can change course sooner.
Overview
Onc.AI develops deep learning radiomics models trained on a large oncology real world dataset. Its Serial CT Response Score analyses sequential CT scans to assess response to immunotherapy in non small cell lung cancer earlier than RECIST based reads and received FDA Breakthrough Device Designation in February 2025. Products are Onclara IO, which predicts response and outcomes for metastatic lung cancer patients starting immunotherapy, and Onclara Evaluate for go or no go decisions in phase 1b and 2 trials; all remain investigational. Validation has been presented at AACR 2025 (with GSK) and ASCO 2025 and 2026 on Flatiron Health data. Onc.AI operates from the San Francisco Bay Area and Waterloo, Ontario. It raised a USD 6 million seed in November 2020 and a USD 25 million Series A in January 2023, received a USD 2 million NCI SBIR grant in 2024, and names MassMutual and GSK among its investors.
Headquarters
San Francisco, CA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- The seed and Series A pages carry only a headline; dates were taken from the WordPress post metadata (2020-11-05 and 2023-01-01) and investor names (MassMutual, GSK) from the company homepage. HQ given as 'SF Bay Area' on the site, recorded as San Francisco. Founding year not sourced. FDA Breakthrough designation date is from the homepage summary; the dedicated page did not render text.
Similar pages
- TrialHC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Shares PD-L1, Non-small-cell lung cancer.
- CompanyOncoHost
Shares PD-L1, PD-1, Non-small-cell lung cancer.
- PersonGordon J. Freeman
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
- TrialAn Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
- TrialA Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
Shares PD-L1, PD-1, Non-small-cell lung cancer.
- TrialImaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Shares PD-L1, PD-1, Non-small-cell lung cancer.
- InstitutionShanghai Pulmonary Hospital
Shares CT (computed tomography), PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PairingCaution: checkpoint inhibitors in first-line ovarian cancer
Shares PD-L1, PD-1, Immune checkpoint inhibitors.